Chunmeng Wang

No. 28 Fuxing Road
Beijing, 100853, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

Journal: Science advances
Published: May 08, 2026

Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.

Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.

Journal: Cellular & molecular immunology
Published: January 19, 2026

Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Journal: American journal of hematology
Published: December 01, 2025

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Journal: Nature communications
Published: November 02, 2025

Manganese mediates nucleoplasm distribution of cGAS to enhance systemic antitumor immunity and drive abscopal effect.

Manganese mediates nucleoplasm distribution of cGAS to enhance systemic antitumor immunity and drive abscopal effect.

Journal: Cancer letters
Published: June 06, 2025

Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome.

Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome.

Journal: Cell reports. Medicine
Published: April 23, 2025

Platelet-to-Neutrophil Ratio: A Novel Prognostic Indicator for Anti-PD-1-Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors.

Platelet-to-Neutrophil Ratio: A Novel Prognostic Indicator for Anti-PD-1-Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors.

Journal: MedComm
Published: September 06, 2024

Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy.

Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy.

Journal: Cell
Published: June 26, 2024

Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma.

Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma.

Journal: Blood
Published: February 28, 2024

Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation.

Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation.

Journal: MedComm
Published: July 02, 2023

Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.

Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.

Journal: Signal transduction and targeted therapy
Published: May 14, 2023

IL-6 translation is a therapeutic target of human cytokine release syndrome.

IL-6 translation is a therapeutic target of human cytokine release syndrome.

Journal: The Journal of experimental medicine
Published: April 05, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026